The pathogenesis of post-lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin-cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.
Lumbar puncture is considered a relatively safe procedure that is commonly performed to assess the chemistry, cell numbers and composition of cerebrospinal fluid (CSF). Furthermore, lumbar puncture is routinely done to administer intrathecal anesthesia, chemotherapy, and to measure the CSF pressure. Serious adverse events occur rarely. They include the introducing of infection into the spinal canal either via a spinal needle, or from traumatic rupture of a perispinal blood vessels in patients with bacteremia. Also, spinal epidural hematomas, subdural hematoma, and subarachnoid hematomas are potentially serious but rare complications after lumbar puncture and had been reported mostly in the setting of coagulopathy, or in patients treating with antiplatelet or anticoagulants (Adler et al., 2001; Paal et al., 2006) . Lower back discomfort and pain occur with frequencies of up to 13% (Dripps & Vandam, 1951) . The most frequent adverse event associated with lumbar punctures is a post-lumbar puncture headache (PLPH), with a published incidence as high as 70% (Fishman, 1992) .
At least two factors that increase the frequency of PLPH have been identified: (1) the diameter, and (2) the tip of the spinal needle. In 1979, Nolte reported an incidence of PLPH of 26% using needles larger than 20 gauge (Nolte, 1979) . In contrast, PLPH occurred with a frequency of 8.5% when 22 gauge or smaller spinal needles were employed.
As early as 1926, Greene started using spinal needles in which the cutting bevels of the needle were rounded, forming a cone like tip that did not cut but spread the fibers of the dural sac (Greene, 1926) . Greene reported a frequency of PLPH of 0.9% in a series of 215 patients. More recently in 2001, the frequency of PLPH in a patient cohort of 115 patients punctured with an atraumatic 22-gauge Sprotte needle was 12.2%, compared to 24.4% in 115 patients punctured with a traumatic Quinke needle (Strupp et al., 2001) .
The pathogenesis of PLPH has remained unclear. It is thought that trauma to the dural sac during the procedure results in a prolonged CSF leakage, and a subsequent decline in CSF pressure. Subsequent events, including dilation of intracranial arteries and veins may trigger pain. The prevention of CSF outflow and ongoing CSF production may prevent or ameliorate PLPH.
A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. Leblanc et al. showed in a prospective multicenter trial that CSF leukocyte pleocytosis during the course of viral meningitis significantly lowers the frequency of PLPH (LeBlanc et al., 2005 (Stuve et al., 2007) . In this cohort, three patients (13%) required an epidural blood patch. Fourteen months after the last administration of natalizumab, 9 patients underwent a second lumbar puncture, and the frequency of PLPH at that time was 11%. The absolute number of white blood cells in CSF was significantly lower at the time of the first lumbar puncture. These data further suggested that the absolute number of leukocytes within the CSF may determine the overall risk of developing PLPH.
The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594) (D'Haens GV et al., 2014) . PF-00547659 is a human monoclonal antibody that binds to mucosal addressin-cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. We made additional observations on the potential pathogenic role of intrathecal leukocytes on PLPH. In cohort 1, CSF was obtained from 5 volunteers with Crohn's disease (CD) who underwent two lumbar punctures (LP) with a 14-day interval, and subsequently received treatment with PF-00547659 (Table 1) . In cohort 2, 32 additional patients with CD were enrolled, and CSF was collected via LP before and after three 225-mg doses of PF-00547659. Drug was administered at least 24 h after the first LP, and then every 28 days (Table 1) .
Changes in overall leukocyte counts and in cellular subsets in cerebrospinal fluid (CSF) were analyzed by multi-parameter flow cytometry. As per the study protocol, lumbar punctures were performed on an inpatient basis, either in a clinical research unit (CRU), or a hospital inpatient unit. Lumbar punctures had to be performed by highly-qualified neurologists or anesthesiologists who perform this procedure on a frequent and regular basis. All lumbar punctures were performed using a 22 G × 90 mm/3.5″ Gertie Marx spinal anesthesia needle with introducer (http://www.imd-nc.com/spinalanesthesia.php).
In our study, the incidence of a PLPH, defined as the presence of a headache or diagnosis of PLPS within 72 h of the procedure, was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. The difference in PLPH rate was not statistically significant. The interval between the first and second lumbar puncture had no significant effect on PLPH incidence. Only one subject (2%) required an epidural blood patch. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 + , CD4 + , and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy.
Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.
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